Download PDF
Nuklearmedizin 1986; 25(05): 167-171
DOI: 10.1055/s-0038-1624336
Originalarbeiten - Original Articles
Schattauer GmbH

Clinical Results of Immunoscintigraphy in a Variety of Malignant Tumors with Special Reference to Immunohistochemistry[*]

H. J. Biersack
1   From the Inst. Clin, and Exp. Nuclear Medicine, Univ. Bonn, England
,
A. Bockisch
1   From the Inst. Clin, and Exp. Nuclear Medicine, Univ. Bonn, England
,
P. Oehr
1   From the Inst. Clin, and Exp. Nuclear Medicine, Univ. Bonn, England
,
A. Knoblich
2   The Dept. of Surgery Univ. Bonn, London, England
,
J. Hartlapp
3   The Dept of Internal Medicine Univ. Bonn, London, England
,
H. Biltz
4   The Dept. of Dermatology Univ. Bonn, London, England
,
N. Jaeger
5   The Dept. of Urology Univ. Bonn, London, England
,
O. Bellmann
6   The Dept of Gynaecol, and Obstet. Univ. Bonn, London, England
,
J. Vogel
7   The Dept. of Pathology Univ. Bonn, London, England
,
B. Björklund
8   F.R.G., the Nat. Bac. Lab./Cancer Immunol. Sec. Stockholm, Sweden
,
J. Taylor-Papadimitriou
9   The Imp. Cancer Res. Fund Lab., London, England
,
C. Winkler
1   From the Inst. Clin, and Exp. Nuclear Medicine, Univ. Bonn, England
› Author Affiliations
Further Information

Publication History

Received: 30 June 1986

Publication Date:
12 January 2018 (online)

    Permissions and Reprints

Radioimmunoscintigraphy was performed in 52 patients with a variety of malignant tumors (colorectal, melanoma, lung, testicular, ovarian, bladder, carcinoid). Respective antibodies or their F(ab’)2 fragments against CEA (n = 23), melanoma antigen 225.28 S (n = 18), TPA (n = 4), ßHCG (n = 5) and HMFG2 (n = 2) were selected by immunohistochemistry of the primary tumor. Most patients were suspected of recurrence or of hitherto unknown distant or local metastases. Overall accuracy was 61 % (32/52). False negatives amounted to 33% (17/52). Useful additional clinical information – not available by CT, ultrasonics or serum levels of tumor markers – was obtained in 17 out of 52 patients (= 33%). From these results it seems obvious that antibodies used for radioimmunoscintigraphy should be selected on the basis of immunohistochemistry.

Zusammenfassung

Bei 52 Patienten mit unterschiedlichen malignen Tumoren (Kolorektal, Melanom, Hoden, Ovar, Blase, Karzinoid, Lunge) wurde eine Radioimmunszintigraphie durchgeführt. Die entsprechenden Antikörper oder deren F(ab’)2-Fragmente gegen CEA (n = 23), Melanomantigen 225.28 S (n = 18), TPA (n = 4), ßHCG (n = 5) und HMFG2 (n = 2) wurden anhand immunhistochemischer Untersuchungen des Primärtumors ausgewählt. Bei allen Patienten bestand der Verdacht auf ein Rezidiv oder bislang unbekannte Lokal- oder Fernmetastasen. Die Treffsicherheit betrug 61% (32/ 52). Falsch negative Befunde wurden in 17 von 52 Fällen festgestellt (33%). Zusätzliche wichtige klinische Informationen, die weder durch CT, Ultraschall oder erhöhte Serumwerte für Tumormarker zu erhalten waren, konnten in 33% der Fälle gewonnen werden. Diese Ergebnisse machen deutlich, daß vor Durchführung der Radioimmunszintigraphie zur Suche nach Rezidiven oder Metastasen entsprechende Tumorantikörper anhand immunhistochemischer Untersuchungen des Primärtumors ausgewählt werden sollten.

* Presented at the Symposium on Monoclonal Antibodies in Nuclear Medicine in Freiburg i. Br., May 1-3, 1986.


 

  • REFERENCES

  • 1 Armitage N. C., Perkins A. C., Pimm M. V., Baldwin R. W., Hardcastle J. D.. Imaging of bone and soft tissue tumors using an antitumor monoclonal antibody. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 215-22 Springer; Berlin-Heidelberg-New York-Tokyo: 1986
    Google Scholar
  • 2 Baum R. P., Maul F. D., Senekowitsch R., Lorenz M., Hottenrott C., Happ J., Standke R., Chatal J. F., Saccavini J. C., Kriegel H., Hör G.. Radioimmunoscintigraphy of CA 19-9/CEA producing tumors using 131I-labeled F(ab’)2 fragments of monoclonal antibodies (19-9/ Anti-CEA radioimmunococktail). In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 197-206 Springer; Berlin- Heidelberg-New York-Tokyo: 1986
    Google Scholar
  • 3 Bischof-Delaloye A., Delaloye B., Buchegger F., von Fliedner V., Mach J-P.. Immunoscintigraphy of CEA-producing tumors with special emphasis on the use of Mab fragments and ECT. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 150-5 Springer; Berlin- Heidelberg-New York-Tokyo: 1986
    Google Scholar
  • 4 Buraggi G. L., Callegaro L., Cascinelli N., Ferrone S., Turrin A., Attili A., Bombardieri E., Gasparini M., Deleide G., Scassellati G. A., Seregni E.. Radioimmunodetection of malignant melanoma with radiolabeled (131I, 123I, 111I, 99mTc) monoclonal antibodies and F(ab’)2 fragments. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 207-14 Springer; Berlin-Heidelberg-New York- Tokyo: 1986
    Google Scholar
  • 5 Critchley M., Brownless S., Patten M., McLaughlin P. J., Tromans P. M., McDicken I. W., Johnson P. M.. Radionuclide imaging of epithelial ovarian tumours with 123I-labelled monoclonal antibody (H317) specific for placental-type alkaline phosphatase. Clin. Radiol. 1986; 37: 107-12.
    CrossrefPubMedGoogle Scholar
  • 6 DeLand F. H., Goldenberg D. M.. In vivo cancer diagnosis by radioimmunodetection. In: Radioimmunoimaging and Radioimmunotherapy. Burchiel S. W., Rhodes B. A.. eds. 329-43 Elsevier Press; New York: 1983
    Google Scholar
  • 7 Goldenberg D. M., DeLand F. H., Kim E. E.. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. New Engl. J. Med. 1978; 298: 1384-8.
    CrossrefPubMedGoogle Scholar
  • 8 Granowska M., Nimmon C. C., Britton K. E.. Immunoscintigraphy of ovarian cancer by means of HMFG2 monoclonal antibody. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 171-6 Springer; Berlin-Heidelberg-New York- Tokyo: 1986
    Google Scholar
  • 9 Halpern S. E., Dillman R. O., Witztum K. F., Shega J. F., Hagan P. L., Burrows W. M., Dillman J. B., Clutter M. L., Sobol R. E., Frincke J. M., Bartholomew R. M., David G. S., Carlo D. J.. Radioimmunodetection of melanoma utilizing In-111 96.5 monoclonal antibody. Radiology 1985; 155: 493-9.
    CrossrefPubMedGoogle Scholar
  • 10 Larson S. M., Brown J. P., Wright P. W., Carrasquillo J. A., Hellström I., Hellström K. E.. Imaging of melanoma with 131I-labeled monoclonal antibodies. J. nucl. Med. 1983; 24: 123-9.
    PubMedGoogle Scholar
  • 11 Larson S. M., Carrasquillo J. A., Reynolds J. C., Hellström I., Hellström K. E.. Radioimmunoscintigraphy by means of melanoma antibody. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 187-96 Springer; Berlin-Heidelberg- New York-Tokyo: 1986
    Google Scholar
  • 12 Mach J. P., Carrel S., Forni N., Ritschard J., Donath A., Alberto P.. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma. New Engl. J. Med. 1980; 303: 5-10.
    CrossrefPubMedGoogle Scholar
  • 13 Mach J. P., Buchegger F., Forni N.. The use of radiolabeled monoclonal anti- CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol. Today 1981; 239-48.
    PubMedGoogle Scholar
  • 14 Mach J. P., Chatal J. F., Lumbroso J. D.. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res. 1983; 43: 5593-600.
    PubMedGoogle Scholar
  • 15 Oehr P., Vogel J., Lichius A., Selbach B., Biersack H. J., Winkler C., Gedigk P.. Vorkommen und Bedeutung von Thyreoglobulin, Tissue Polypeptide Antigen, karzinoembryonalem Antigen und Calcitonin in Geweben und im Plasma von Schilddrüsenkarzinom-Patienten. Tumor. Diagn. Ther. 1984; 05: 129-38.
    Google Scholar
  • 16 Perkins A. C., Powell M. C., Pimm M. V., Wastie M. L., Symonds E. M., Baldwin R. W.. Immunoscintigraphy of gynaecological tumors. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 177-86 Springer; Berlin-Heidelberg- New York-Tokyo: 1986
    Google Scholar
  • 17 Pressman D., Korngold L.. The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer. 1953; 06: 619-23.
    CrossrefPubMedGoogle Scholar
  • 18 Wellman H. N., Lin L., Rowland R., Sledge G.. Beta-HCG and related germcell tumor antigens in radioimmunodetection. In: Nuclear Medicine in Clinical Oncology – Current Status and Future Aspects. Winkler C.. ed. 156-63 Springer; Berlin-Heidelberg-New York- Tokyo: 1986
    Google Scholar